Double-dose targeted therapy with or without spinal fluid chemotherapy for lung cancer that has spread to the brain lining
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests whether giving a higher dose of an EGFR-targeted pill, either alone or with a chemotherapy drug injected into the fluid around the spinal cord, can control lung cancer that has spread to the lining of the brain (called leptomeningeal metastases). It is for people whose cancer has gotten worse in the brain lining while on a standard dose of this type of medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread to the brain or spinal cord lining and has progressed after prior treatment with a third-generation EGFR-targeted pill (like osimertinib).
- Your cancer must have a specific EGFR mutation (exon 19 deletion or L858R).
- Your performance status (how well you can do daily activities) must be 0 to 3, meaning you are at least up and about more than half the day.
- Your organ function must be within acceptable limits as determined by blood tests.
- You must be willing to use effective birth control if you or your partner could become pregnant.
- You must be able to swallow pills (or take them through a stomach tube if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stronger dose of an EGFR-targeted drug combined with bevacizumab and chemotherapy into the spinal fluid for patients with non-small cell lung cancer that has spread to the lining of the brain and is no longer responding to standard treatment.
This Phase 2 trial tests giving pemetrexed directly into the spinal fluid to treat cancer that has spread to the brain’s and spinal cord’s lining (leptomeningeal metastasis). It is for people with EGFR-mutant non-squamous lung cancer whose disease progressed after osimertinib, and who may benefit from a targeted treatment delivered to the area affected in the brain lining.
This trial tests a drug called pemetrexed, given directly into the fluid around the spinal cord (intrathecal), for people with lung cancer that has spread to the brain and spinal cord lining and is no longer controlled by the targeted therapy osimertinib.
This trial tests combining a targeted pill (firmonertinib) with medication injected into the fluid around the spine for people with a specific type of lung cancer that has spread to the lining of the brain. It may offer a new option if you have already tried other EGFR drugs and are still having progression.
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
This study tests whether a chemotherapy drug called thiotepa, given directly through a small device in the scalp (called an Ommaya reservoir), can safely and effectively treat lung cancer that has spread to the fluid around the brain and spinal cord. It's for people whose cancer has stopped responding to standard EGFR-targeted pills.
Hear when a new Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.